- Home
- NIPG vs TCRX Comparison
NIPG vs TCRX Comparison
Compare NIPG & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIPG
- TCRX
- Stock Information
- Founded
- NIPG 2014
- TCRX 2018
- Country
- NIPG Sweden
- TCRX United States
- Employees
- NIPG N/A
- TCRX N/A
- Industry
- NIPG
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- NIPG
- TCRX Health Care
- Exchange
- NIPG NYSE
- TCRX Nasdaq
- Market Cap
- NIPG 96.4M
- TCRX 82.1M
- IPO Year
- NIPG 2024
- TCRX 2021
- Fundamental
- Price
- NIPG $2.35
- TCRX $1.78
- Analyst Decision
- NIPG Strong Buy
- TCRX Strong Buy
- Analyst Count
- NIPG 1
- TCRX 6
- Target Price
- NIPG $6.00
- TCRX $9.50
- AVG Volume (30 Days)
- NIPG 409.0K
- TCRX 633.8K
- Earning Date
- NIPG 04-30-2025
- TCRX 08-11-2025
- Dividend Yield
- NIPG N/A
- TCRX N/A
- EPS Growth
- NIPG N/A
- TCRX N/A
- EPS
- NIPG N/A
- TCRX N/A
- Revenue
- NIPG $85,266,306.00
- TCRX $4,421,000.00
- Revenue This Year
- NIPG $11.25
- TCRX $159.20
- Revenue Next Year
- NIPG $33.33
- TCRX N/A
- P/E Ratio
- NIPG N/A
- TCRX N/A
- Revenue Growth
- NIPG 1.91
- TCRX N/A
- 52 Week Low
- NIPG $0.99
- TCRX $1.02
- 52 Week High
- NIPG $17.76
- TCRX $7.89
- Technical
- Relative Strength Index (RSI)
- NIPG N/A
- TCRX 63.04
- Support Level
- NIPG N/A
- TCRX $1.45
- Resistance Level
- NIPG N/A
- TCRX $1.94
- Average True Range (ATR)
- NIPG 0.00
- TCRX 0.13
- MACD
- NIPG 0.00
- TCRX 0.04
- Stochastic Oscillator
- NIPG 0.00
- TCRX 87.20
About NIPG NIP GROUP INC SPON ADS EACH REPR 2 CL A ORD SHS
NIP Group Inc is a digital entertainment company built for the growing gaming and esports industry. NIP Group integrates multiple businesses such as talent agency, event production, game-themed hotels and game publishing to create transformative entertainment experiences that inspire, connect fans, expand influence globally, and achieve deep interaction on platforms where digital native players gather. It currently has operation centers in Sweden, China, Abu Dhabi, and Brazil, and its esports teams cover multiple game projects and are active in the top event stages.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.